Nelitolimod: all 25 studies that test it
Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.
- An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis BullosaNot yet recruitingNCT07482813Phase 3
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis BullosaRecruitingNCT07482787Phase 3
- INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastasesRecruitingNCT07172282Early Phase 1
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With LymphomaCompletedNCT03322384Phase 1/2Results posted
- Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTCompletedNCT03007732Phase 2Results posted
- TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaCompletedNCT02927964Phase 1/2Results posted
- Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)TerminatedNCT02731742Phase 1Results posted
- Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis BullosaTerminatedNCT02670330Phase 3Results posted
- A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT02521870Phase 1/2Results posted
- ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis BullosaCompletedNCT02384460Phase 3Results posted
- Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell LymphomaTerminatedNCT02266147Phase 1/2Results posted
- A Phase I/II Study of Intratumoral Injection of SD-101CompletedNCT02254772Phase 1/2Results posted
- Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis BullosaTerminatedNCT02090283Phase 2Results posted
- Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis BullosaCompletedNCT02014376Phase 2Results posted
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and TremelimumabActive, not recruitingNCT06710223Phase 1
- Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic AdenocarcinomaActive, not recruitingNCT05607953Phase 1
- Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsTerminatedNCT05220722Phase 1/2
- Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaTerminatedNCT04935229Phase 1
- SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic CancerCompletedNCT04050085Phase 1
- SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid MalignanciesCompletedNCT03831295Phase 1
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT03410901Phase 1
- Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)TerminatedNCT01745354Phase 1
- Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT00823862Phase 1
- Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal MalesCompletedNCT00599001Phase 1